Seven sites in Australia are now active and screening patients for the BR31 study, with the remaining sites on track to be up and running by the end of the year. This study continues the ALTG’s highly successful collaboration with the Canadian NCIC-CTG.
The ALTG-led Phase 3 NITRO study was published in the Annals of Oncology – congratulations and thanks to the investigators, site staff and patients for their contribution to this trial. A parallel study conducted by the Dutch NVALT group was also published in the same issue of the Annals.
On the international front, two important events took place during early September – the World Conference on Lung Cancer in Denver, Colorado and formal establishment of the international cooperative trials group for thoracic oncology, TACT (the Thoracic Alliance for Cancer Trials). In addition to establishing the inaugural Board and opening applications for membership, a series of meetings with regulatory and industry stakeholders to discuss this important global initiative was held while in Denver.
The ALTG continues to work closely with lead investigators and the NHMRC CTC to develop new trial ideas and in this issue of the newsletter we provide an update of concepts that are currently in development. We have built some momentum in this area over the past 12 months and to keep things moving we are holding a full-day workshop in Melbourne on November 13 to brainstorm and prioritise ideas for future clinical trials by the group. Be sure to join us if you haven’t already made plans to do so – all ideas are welcome!